Related Experiment Video
Updated: Jan 13, 2026

06:51
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
8.1K
AMT-130 gene therapy: a promising disease-modifying approach for Huntington's disease
Chisanga Mwape1, Afnan Ahmad Qureshi2, Muhammad Zaid Saeed2
1Department of Internal Medicine, The Copperbelt University School of Medicine, Ndola, Zambia.
Annals of Medicine and Surgery (2012)
|January 7, 2026
Summary
AMT-130 gene therapy offers a novel approach for Huntington's disease (HD) by reducing mutant huntingtin protein. Early clinical data suggest a potential to slow disease progression, moving beyond symptomatic treatment.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Huntington's disease (HD) is a progressive neurodegenerative disorder caused by expanded CAG repeats in the huntingtin (HTT) gene.
- Current treatments for HD are primarily symptomatic, lacking disease-modifying therapies.
- Mutant huntingtin protein accumulation leads to neuronal dysfunction and loss in HD.
Related Concept Videos
Gene Therapy
27.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.3K
Parkinson's Disease: Treatment
970
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
970
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806

